NLP SNP

Report for SNP rs1024611

Developed by Shray Alag, 2020.

SNP Clinical Trial Gene

There are 2 clinical trials

Clinical Trials

1 A Randomized, Double-Blind Placebo- Controlled Phase 2a Study to Assess the Effect of CCR2 Antagonism by MLN1202 on Atherosclerotic Inflammation in Subjects With Stable Atherosclerotic Cardiovascular Disease Using FDG PET/CT Imaging

The purpose of this study is to evaluate the effect of MLN1202 on arterial inflammation in participants with stable atherosclerotic cardiovascular disease (CVD) who are receiving standard-of-care (SOC) therapy.

NCT02388971 Atherosclerotic Cardiovascular Disease Drug: MLN1202 Drug: Placebo

MeSH: Atherosclerosis Inflammation Cardiovascular Diseases

HPO: Abnormality of the cardiovascular system Atherosclerosis Type IV atherosclerotic lesion

The change in arterial FDG uptake from MLN1202 treatment relative to placebo, comparing pretreatment and 3 month post-treatment time points in subjects identified using a dominant model of the snip in the MCP-1 polymorphisms [MCP-1 -2518 (rs1024611)].. null.

Primary Outcomes

Description: The primary imaging endpoint of interest is the FDG uptake, measured as a target to background ratio (TBR) within the most diseased segment (MDS) of the index vessel.

Measure: The change in arterial FDG uptake from MLN1202 treatment relative to placebo, comparing pretreatment and 3 month post-treatment time points

Time: Baseline and 3 month post-treatment

Secondary Outcomes

Measure: The change in arterial FDG uptake from MLN1202 treatment relative to placebo, comparing pretreatment and 3 month post-treatment time points in subjects identified using a dominant model of the snip in the MCP-1 polymorphisms [MCP-1 -2518 (rs1024611)].

Time: Baseline and 3 month post-treatment

Description: Average mean of the maximum TBR in the MDS of the combined right and left carotid artery walls will be measured using 2-deoxy-2-[18F]-fluoro-D-g1ucose positron emission tomography/computed tomography (FDG PET/CT).

Measure: Change from Baseline in Mean Carotid Vessel MDS TBR

Time: Baseline and Day 82

Description: TBR will be measured in both ascending aorta and carotids with demonstrable inflammation at Baseline using FDG PET/CT.

Measure: Change from Baseline in Mean Active Segment TBR

Time: Baseline and Day 82

Description: FDG uptake in the artery wall within the entire index vessel will be measured using FDG PET/CT.

Measure: Change from Baseline in Mean Index Vessel TBR

Time: Baseline and Day 82

Description: The average mean of the maximum TBR and the MDS of the combined right and left carotid artery walls will be measured using FDG PET/CT.

Measure: Change from Baseline in Mean Carotid Vessel TBR

Time: Baseline and Day 82

2 Clinical and Genetic Factors Associated With Drug Resistance of Epilepsy

This study is to identify the clinical criteria of drug resistant epilepsy and to explore whether SCN1A c.3184 A/G (rs2298771) and ccl2(rs1024611) polymorphisms could serve as genetic based biomarkers to predict drug resistance among epileptic patient.

NCT04166305 Epilepsy, Drug Resistant Genetic: Genetic study for SCN1A c.3184 A/G and CCL2-2518G>A polymorphism:

MeSH: Epilepsy Drug Resistant Epilepsy

HPO: Focal sensory seizure Seizures

Drug Resistant Epilepsy: Clinical and Genetic Study This study is to identify the clinical criteria of drug resistant epilepsy and to explore whether SCN1A c.3184 A/G (rs2298771) and ccl2(rs1024611) polymorphisms could serve as genetic based biomarkers to predict drug resistance among epileptic patient.

Primary Outcomes

Description: • DNA analysis: Genomic DNA will be extracted from EDTA-anticoagulated peripheral blood (QIAamp DNA Blood mini kit,QIAGEN). • Genotyping of SCN1A c.3184 A/G(rs2298771) polymorphism

Measure: Genetic study for SCN1A c.3184 A/G and CCL2-2518G>A polymorphism:

Time: 5-7 days